FDA approves supplement 6 for Pharming's Joenja tablets
The efficacy supplement for leniolisib phosphate, reviewed under priority status, was approved with an application letter and label dated September 15, 2026.
The U.S. Food and Drug Administration approved a sixth supplement to the new drug application for Joenja, according to agency records. The submission, filed under NDA217759, is listed as an efficacy submission type and was reviewed under priority review.1
Joenja is an oral tablet containing leniolisib phosphate at a strength equivalent to 70 mg base, sponsored by Pharming.1
The FDA's submission status date for this action is listed as September 11, 2026, while the associated approval letter and product label documents in the agency's records carry a date of September 15, 2026.1 The record does not explain the discrepancy between these two dates.
No additional details on the clinical basis for the supplement, dosing changes, or labeling updates were included in the available FDA record. Readers seeking the specific rationale for the efficacy supplement would need to consult the linked approval letter and label documents directly for further specifics.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.